> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Panel to Discuss Kidney Disease Drug
- URL: https://www.fdaweb.com/fda-panel-to-discuss-kidney-disease-drug/
- Published: 2022-09-16T12:00:00.000Z
- Updated: 2026-09-14T17:59:39.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5152757

*Federal Register* notice: FDA has announced an 11/16 Cardiovascular and Renal Drugs Advisory Committee meeting to discuss an Ardelyx NDA for tenapanor hydrochloride tablets and its use in controlling serum phosphorus levels in adults with chronic kidney disease on dialysis. Panel members will be asked to comment on whether the size of the treatment effect on serum phosphorus is clinically meaningful and whether tenapanor’s benefits outweigh its risks. To view the notice, click [here](https://public-inspection.federalregister.gov/2022-20198.pdf?ref=fdaweb.com).